This decision, involving the antipsychotic drug ABILIFY, is a further example of the fact that it is not difficult to obtain a preliminary injunction in a case involving pharmaceuticals that are covered by the Australiuan government's Pharmaceutical Benefits Scheme. The significant and irreversible impact of government regulations on the price at which the patented drugs can be sold has been found repeatedly to tip the balance of convenience in favour of the patentee, resulting in the grant of injunctions.
Shared publicly